Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study-Reference-Cited by-同舟云学术

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study

Published:2023-07 Issue: Volume:61 Page:102043
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Ding Xi,Hua Yi-Jun,Zou Xiong,Chen Xiao-Zhong,Zhang Xi-Mei,Xu Bei,Ouyang Yan-Feng,Tu Zi-Wei,Li Hui-Feng,Duan Chong-Yang,Zhang Wei-Jing,You Rui,Liu You-Ping,Liu Yong-Long^ORCID,Yang Qi,Huang Pei-Yu^ORCID,Wang Shu-Ni,Fan Jia,Chen Ming-Yuan^ORCID

Funder

Jiangsu Hengrui Medicine

Publisher

Elsevier BV

Subject

General Medicine

Reference42 articles.

1. Global cancer observatory: cancer today;Ferlay,2020

2. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

3. Management of locally recurrent nasopharyngeal carcinoma;Lee;Cancer Treat Rev,2019

4. Prognostic model for stratification of radioresistant nasopharynx carcinoma to curative salvage radiotherapy;Li;J Clin Oncol,2018

5. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial;Mai;Nat Med,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-L1 expression as a potential predictor of immune checkpoint inhibitor efficacy and survival in patients with recurrent or metastatic nasopharyngeal cancer: a systematic review and meta-analysis of prospective trials;Frontiers in Oncology;2024-06-03

2. The efficacy and safety of EGFR‐TKI in recurrent/metastatic nasopharyngeal carcinoma patients: A systematic review and meta‐analysis;Laryngoscope Investigative Otolaryngology;2024-05-27

3. Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1 resistant recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II clinical trial;2024-04-12

4. Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy;Scientific Reports;2024-01-20

5. Critical review of the current and future prospects of VEGF-TKIs in the management of squamous cell carcinoma of head and neck;Frontiers in Oncology;2023-12-13